TABLE 3.
Determination of capsular polysaccharide type 5 or 8 by agglutination tests (serotype) and PCR (genotype) among 195 clinical isolates (126 MSSA and 69 MRSA)
| Method | Isolate group | No. (%) of isolates
|
||
|---|---|---|---|---|
| Capsular type 5 | Capsular type 8 | Nontypeablec | ||
| Agglutinationa | MSSA isolates | 37 (29.3) | 76 (60.3) | 13 (6.5)* |
| MRSA isolates | 44 (64) | 12 (17) | 13 (6.5)* | |
| Total isolates | 81 (42) | 88 (45) | 26 (13)* | |
| PCRb | MSSA isolates | 37 (29.3) | 89 (71) | 0 |
| MRSA isolates | 52 (75) | 17 (25) | 0 | |
| Total isolates | 89 (46) | 106 (54) | 0 | |
a
Serological typing by agglutination with antisera specific to capsular type 5 or type 8.
b
Detection of capsule genotype with primers located in specific locus cap5 or cap8.
c
*, Nontypeable by agglutination with antibodies specific for capsular polysaccharide type 5 or 8 but reacted positively with 336 polyclonal antibodies, and all carried the cap8 or cap5 genes.